ATE401875T1 - Pharmazeutische feste dispersionen von modafinil- verbindungen - Google Patents
Pharmazeutische feste dispersionen von modafinil- verbindungenInfo
- Publication number
- ATE401875T1 ATE401875T1 AT03810805T AT03810805T ATE401875T1 AT E401875 T1 ATE401875 T1 AT E401875T1 AT 03810805 T AT03810805 T AT 03810805T AT 03810805 T AT03810805 T AT 03810805T AT E401875 T1 ATE401875 T1 AT E401875T1
- Authority
- AT
- Austria
- Prior art keywords
- solid dispersions
- pharmaceutical solid
- modafinil compounds
- modafinil
- compounds
- Prior art date
Links
- YFGHCGITMMYXAQ-UHFFFAOYSA-N 2-[(diphenylmethyl)sulfinyl]acetamide Chemical class C=1C=CC=CC=1C(S(=O)CC(=O)N)C1=CC=CC=C1 YFGHCGITMMYXAQ-UHFFFAOYSA-N 0.000 title abstract 3
- 239000007962 solid dispersion Substances 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229960001165 modafinil Drugs 0.000 abstract 1
- -1 modafinil compound Chemical class 0.000 abstract 1
- 239000003960 organic solvent Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Nutrition Science (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/286,573 US6919378B2 (en) | 2000-10-11 | 2002-11-01 | Pharmaceutical solutions of modafinil compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE401875T1 true ATE401875T1 (de) | 2008-08-15 |
Family
ID=32312077
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03810805T ATE401875T1 (de) | 2002-11-01 | 2003-10-24 | Pharmazeutische feste dispersionen von modafinil- verbindungen |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US6919378B2 (de) |
| EP (1) | EP1562572B1 (de) |
| JP (1) | JP2006507300A (de) |
| CN (1) | CN100423717C (de) |
| AT (1) | ATE401875T1 (de) |
| AU (1) | AU2003301817B2 (de) |
| CA (1) | CA2503719C (de) |
| DE (1) | DE60322412D1 (de) |
| ES (1) | ES2310687T3 (de) |
| MX (1) | MXPA05004697A (de) |
| NZ (1) | NZ539778A (de) |
| WO (1) | WO2004041245A2 (de) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUP0400927A3 (en) | 2000-07-27 | 2007-11-28 | Teva Pharma | New crystalline form and pure modafinil, process of preparing them, and pharmaceutical compositions containing the new crystalline form |
| CA2418490A1 (en) * | 2000-08-11 | 2002-02-21 | Eisai Co., Ltd. | Drug-containing solid dispersion having improved solubility |
| US20040116532A1 (en) * | 2002-09-13 | 2004-06-17 | Craig Heacock | Pharmaceutical formulations of modafinil |
| FR2849029B1 (fr) * | 2002-12-20 | 2005-03-18 | Lafon Labor | Procede de preparation et formes cristallines des enantiomeres optiques du modafinil. |
| WO2004082630A2 (en) * | 2003-03-17 | 2004-09-30 | Neurohealing Pharmaceuticals, Inc. | High potency dopaminergic treatment of neurological impairment associated with brain injury |
| US20040253308A1 (en) * | 2003-04-29 | 2004-12-16 | Barr Laboratories, Inc. | Surface-treated modafinil particles |
| US20050008704A1 (en) * | 2003-07-11 | 2005-01-13 | Ray Anup Kumar | Pharmaceutical composition for solubility enhancement of hydrophobic drugs |
| US7368591B2 (en) | 2003-09-19 | 2008-05-06 | Cephalon France | Process for enantioselective synthesis of single enantiomers of modafinil by asymmetric oxidation |
| CA2657409A1 (en) * | 2006-07-12 | 2008-01-17 | Elan Corporation, Plc | Nanoparticulate formulations of modafinil |
| JP5593013B2 (ja) * | 2007-04-20 | 2014-09-17 | 株式会社感光社 | 固体型殺菌剤及び人体施用組成物 |
| US8173169B2 (en) * | 2007-07-11 | 2012-05-08 | Hikma Pharmaceuticals | Formulation and process for the preparation of modafinil |
| RU2010123282A (ru) * | 2007-11-09 | 2011-12-20 | Интэрвэт Интэрнэшнл Б.Ф. (NL) | Твердая лекарственная форма с быстрым высвобождением активного вещества, ее получение и применение |
| US20090130048A1 (en) * | 2007-11-19 | 2009-05-21 | Oronsky Bryan Todd | Topical Composition for Treating Pain |
| US8784872B2 (en) * | 2007-11-19 | 2014-07-22 | Comgenrx, Inc. | Formulation for decreasing tobacco, alcohol, drug or food consumption |
| MX2010010050A (es) | 2008-03-20 | 2011-03-15 | Virun Inc Star | Emulsiones que incluyen un derivado de polietilen glicol de tocoferol. |
| CA2715018C (en) | 2008-03-20 | 2012-11-13 | Virun, Inc. | Vitamin e derivatives and their uses |
| WO2009158667A2 (en) * | 2008-06-27 | 2009-12-30 | Comgenrx, Inc. | Povidone compositions for wound healing |
| EP2563164B1 (de) * | 2010-03-23 | 2016-06-29 | Virun, Inc. | Nanoemulsionen enthaltend saccharosefettsäureester |
| US8741373B2 (en) | 2010-06-21 | 2014-06-03 | Virun, Inc. | Compositions containing non-polar compounds |
| WO2013120025A1 (en) | 2012-02-10 | 2013-08-15 | Virun, Inc. | Beverage compositions containing non-polar compounds |
| FR2987266B1 (fr) | 2012-02-28 | 2014-12-19 | Debregeas Et Associes Pharma | Procede d'obtention d'une composition pharmaceutique a base de modafinil, composition pharmaceutique ainsi obtenue et son application |
| FR2987265B1 (fr) | 2012-02-28 | 2014-02-28 | Debregeas Et Associes Pharma | Composition pharmaceutique sous forme de sirop a base de modafinil, son procede de fabrication et son application |
| US9351517B2 (en) | 2013-03-15 | 2016-05-31 | Virun, Inc. | Formulations of water-soluble derivatives of vitamin E and compositions containing same |
| US9693574B2 (en) | 2013-08-08 | 2017-07-04 | Virun, Inc. | Compositions containing water-soluble derivatives of vitamin E mixtures and modified food starch |
| TWI661841B (zh) * | 2017-04-19 | 2019-06-11 | 三凡生技研發股份有限公司 | 用於分散疏水性植物萃取物之載劑 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1584462A (en) | 1977-03-31 | 1981-02-11 | Lafon Labor | N-diaryl-malonamide and diarylmethyl-sulphinyl-acetamide derivatives and pharmaceutical compositions containing them |
| FR2593809B1 (fr) | 1986-01-31 | 1988-07-22 | Lafon Labor | Benzhydrylsulfinylacetamide, procede de preparation et utilisation en therapeutique |
| FR2663225B1 (fr) | 1990-06-14 | 1994-11-04 | Lafon Labor | Nouvelle utilisation du modafinil. |
| US5843347A (en) * | 1993-03-23 | 1998-12-01 | Laboratoire L. Lafon | Extrusion and freeze-drying method for preparing particles containing an active ingredient |
| US5618845A (en) | 1994-10-06 | 1997-04-08 | Cephalon, Inc. | Acetamide derivative having defined particle size |
| US20030077227A1 (en) * | 1997-10-01 | 2003-04-24 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system |
| FR2771004B1 (fr) | 1997-11-19 | 2000-02-18 | Inst Curie | Utilisation de derives de benzhydryl sulfinyle pour la fabrication de medicaments ayant un effet eveillant dans des situations de troubles de la vigilance d'origine medicamenteuse |
| US6200968B1 (en) | 1998-08-06 | 2001-03-13 | Cephalon, Inc. | Particle-forming compositions containing fused pyrrolocarbazoles |
| US6294192B1 (en) * | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
| US7374779B2 (en) * | 1999-02-26 | 2008-05-20 | Lipocine, Inc. | Pharmaceutical formulations and systems for improved absorption and multistage release of active agents |
| US6346548B1 (en) * | 1999-08-16 | 2002-02-12 | Cephalon, Inc. | Compositions including modafinil for treatment of attention deficit hyperactivity disorder and multiple sclerosis fatigue |
| US6455588B1 (en) * | 1999-08-20 | 2002-09-24 | Cephalon, Inc. | Compositions including modafinil for treatment of eating disorders and for appetite stimulation |
| US20010034373A1 (en) | 2000-02-09 | 2001-10-25 | Matthew Miller | Low dose modafinil for enhancement of cognitive function |
| DE60137069D1 (de) | 2000-10-11 | 2009-01-29 | Cephalon Inc | Arzneizusammensetzungen enthaltend modafinilverbindungen |
| US6489363B2 (en) | 2000-10-11 | 2002-12-03 | Cephalon, Inc. | Pharmaceutical solutions of modafinil compounds |
| US20040048931A1 (en) | 2002-07-12 | 2004-03-11 | Craig Heacock | Modafinil pharmaceutical compositions |
| WO2004010979A1 (en) | 2002-07-25 | 2004-02-05 | Ranbaxy Laboratories Limited | Processes for the preparation of oral dosage formulations of modafinil |
-
2002
- 2002-11-01 US US10/286,573 patent/US6919378B2/en not_active Expired - Fee Related
-
2003
- 2003-10-24 AU AU2003301817A patent/AU2003301817B2/en not_active Ceased
- 2003-10-24 WO PCT/US2003/034098 patent/WO2004041245A2/en active Application Filing
- 2003-10-24 AT AT03810805T patent/ATE401875T1/de not_active IP Right Cessation
- 2003-10-24 CN CNB2003801026009A patent/CN100423717C/zh not_active Expired - Fee Related
- 2003-10-24 NZ NZ539778A patent/NZ539778A/en not_active IP Right Cessation
- 2003-10-24 JP JP2004550141A patent/JP2006507300A/ja active Pending
- 2003-10-24 CA CA2503719A patent/CA2503719C/en not_active Expired - Fee Related
- 2003-10-24 MX MXPA05004697A patent/MXPA05004697A/es active IP Right Grant
- 2003-10-24 EP EP03810805A patent/EP1562572B1/de not_active Expired - Lifetime
- 2003-10-24 DE DE60322412T patent/DE60322412D1/de not_active Expired - Lifetime
- 2003-10-24 ES ES03810805T patent/ES2310687T3/es not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| HK1079446A1 (en) | 2006-04-07 |
| NZ539778A (en) | 2007-11-30 |
| MXPA05004697A (es) | 2005-10-18 |
| US20030125391A1 (en) | 2003-07-03 |
| DE60322412D1 (de) | 2008-09-04 |
| CN100423717C (zh) | 2008-10-08 |
| JP2006507300A (ja) | 2006-03-02 |
| US6919378B2 (en) | 2005-07-19 |
| AU2003301817A1 (en) | 2004-06-07 |
| EP1562572B1 (de) | 2008-07-23 |
| CA2503719A1 (en) | 2004-05-21 |
| AU2003301817B2 (en) | 2008-11-20 |
| CN1708295A (zh) | 2005-12-14 |
| WO2004041245B1 (en) | 2004-10-14 |
| CA2503719C (en) | 2012-01-10 |
| EP1562572A2 (de) | 2005-08-17 |
| WO2004041245A3 (en) | 2004-07-15 |
| ES2310687T3 (es) | 2009-01-16 |
| WO2004041245A2 (en) | 2004-05-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60322412D1 (de) | Pharmazeutische feste Dispersionen von Modafinil-Verbindungen | |
| ATE461217T1 (de) | Glp-1-verbindungen | |
| CY1110835T1 (el) | Διφαινυλ παραγωγα και η χρηση τους στη θεραπεια της ηπατιτιδας c | |
| CY1111050T1 (el) | Φωσφονικα, μονοφωσφοναμιδικα, διφωσφοναμιδικα για την αγωγη των ιϊκων παθησεων | |
| HRP20080564T3 (hr) | Dihidrotetrabenazini i farmaceutski pripravci koji ih sadrže | |
| CY2014028I1 (el) | Ενωσεις, φαρμακοτεχνικες μορφες και μεθοδοι θεραπειας ή αποτροπhς ροδοχρωμης ακμης | |
| DE60142913D1 (de) | Arzneilösungen enthaltend modafinilverbindungen | |
| LTPA2013018I1 (lt) | 4-oksochinolino junginiai ir jų, kaip živ inregrazės inhibitorių, panaudojimas | |
| EA200401169A1 (ru) | Аминометилзамещенные тетрациклиновые соединения | |
| CY1108874T1 (el) | ΧΡΗΣΗ ΤΩΝ ΑΝΑΣΤΟΛΕΩΝ Ι κΒ- ΚΙΝΑΣΗΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΠΟΝΟΥ | |
| DE602004027936D1 (de) | Tocopherolmodifizierte therapeutische arzneimittelverbindung | |
| SE0301653D0 (sv) | Novel compounds | |
| DE60334536D1 (de) | Furylverbindungen | |
| DE502004002571D1 (de) | Substituierte 3-pyrrolidin-indol-derivate | |
| CY1110061T1 (el) | Συνθεσεις περιλαμβανοντας ενωσεις μοδαφινιλης | |
| SE0401970D0 (sv) | Novel compounds | |
| ATE303384T1 (de) | 1-biaryl-1,8-naphthyridin-4-one als phosphodieseterase-inhibitoren | |
| WO2003066597A3 (en) | Guanidino compounds | |
| EA200501821A1 (ru) | Фармацевтическая комбинация, содержащая модафинил и другой лекарственный препарат | |
| EA200401319A1 (ru) | Новые гетероциклические соединения, способы их получения и фармацевтические композиции, содержащие эти соединения, и их использование в медицине | |
| EA200500774A1 (ru) | Новая синергетическая комбинация, включающая рофлумиласт и формотерол | |
| EP1364652A4 (de) | Heilmittel gegen lungenkrebs | |
| DK1537132T3 (da) | Salt af mortin-6-glucuronid | |
| EA200601030A1 (ru) | 7α,17α-ЗАМЕЩЁННЫЕ 11β-ГАЛОГЕНОСТЕРОИДЫ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ, ПРИМЕНЕНИЕ И ФАРМАЦЕВТИЧЕСКИЙ ПРЕПАРАТ НА ИХ ОСНОВЕ | |
| NO20071096L (no) | Diarylmetylpiperazinderivater, fremstillinger derav og anvendelser derav |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |